Listen: Biogen’s messy board, Laronde’s data problem, & the downside of a boom
Can unicorns survive without data? Did biotech get over its skis? And what is going on at Biogen?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Allison DeAngelis joins us to share her reporting on how the handsomely funded Laronde Therapeutics, billed as “Moderna 2.0,” ran into behind-the-scenes problems with its scientific data. We also discuss how Biogen’s boardroom scandal has roiled a company that was supposed to be entering a new era.
